Aclaris Q2 Net Loss Expands; Secures FDA's Fast Track Designation For Modzatinib In Lichen Planus

Aclaris Therapeutics reported Q2 results showing a wider net loss, reflecting continued financial pressure. Offsetting that, the FDA granted Fast Track Designation for its lead program, which can support accelerated review pathways. Net-net the update is cautious due to losses widening, but the regulatory milestone provides some positive support for the story.

Analysis

Aclaris Therapeutics reported Q2 results showing a wider net loss, reflecting continued financial pressure. Offsetting that, the FDA granted Fast Track Designation for its lead program, which can support accelerated review pathways. Net-net the update is cautious due to losses widening, but the regulatory milestone provides some positive support for the story.